[Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].
Trabelsi
Sameh
S
Boussen
Hammouda
H
Gaïes
Emna
E
Salouage
Issam
I
El Aïdli
Sihem
S
Daghfous
Riadh
R
Loueslati
Mohamed-Hedi
MH
Lakhal
Mohamed
M
Belkahia
Chelbi
C
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004347:Drug Interactions; D046152:Gastrointestinal Stromal Tumors / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008795:Metronidazole / Q000009:adverse effects*; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D015572:Spiramycin / Q000009:adverse effects*; D000077210:Sunitinib
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D008795:Metronidazole; D015572:Spiramycin; D000077210:Sunitinib